<div></div><div>Ghahestani Seyyed Mohammad*1,Sara Karimi 2,Mohammad Hamidi Madani3</div><div><b>*1:</b> <sup>1</sup>Children Medical Center Hospital, Tehran
University of Medical Sciences (TUMS), Tehran, Iran. Email:
mgrosva@gmail.com.No:+989128491811</div><div>Address: Pediatric Urology Ward,Children Medical Centre Hospital ,Gharib
St, Keshavarz Blvd,Tehran,Iran</div><div>2:Sara Karimi, Alborz University of Medical sciences. E
mail:Sarakarimi1984@yahoo.com</div><div>No:+989133004032</div><div>3: Mohammad Hamidi Madani.Labbafinejad Hospital, Shahid Beheshti
University of Medical Sciences(SBMU). Email:m.hamidimadani70@gmail.com
Phone No:+989393898696</div><div>Abstract:</div><div>In previous publications the role of kininogen system has been
postulated. On those publications the possible role of Icatibant,
Ecallantide and Aprotinin in treatment of SARS Cov-2 has been raised. In
this paper we raise the hypothetical potential of Methylene Blue in
treatment of SARS COV 2. This medication may abort effects of Bradykinin
by inhibition of NO Synthase inhibitor and promote oxygen saturation
while it is inexpensive and ubiquitously accessible. Clinical studies
can not be over emphasized.</div>